- Home
- GKOS vs MSW Comparison
GKOS vs MSW Comparison
Compare GKOS & MSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- MSW
- Stock Information
- Founded
- GKOS 1998
- MSW 2012
- Country
- GKOS United States
- MSW Hong Kong
- Employees
- GKOS N/A
- MSW N/A
- Industry
- GKOS Medical/Dental Instruments
- MSW
- Sector
- GKOS Health Care
- MSW
- Exchange
- GKOS Nasdaq
- MSW NYSE
- Market Cap
- GKOS 5.1B
- MSW N/A
- IPO Year
- GKOS 2015
- MSW 2024
- Fundamental
- Price
- GKOS $90.26
- MSW $3.45
- Analyst Decision
- GKOS Strong Buy
- MSW
- Analyst Count
- GKOS 13
- MSW 0
- Target Price
- GKOS $155.00
- MSW N/A
- AVG Volume (30 Days)
- GKOS 1.0M
- MSW 44.8K
- Earning Date
- GKOS 04-30-2025
- MSW 05-25-2025
- Dividend Yield
- GKOS N/A
- MSW N/A
- EPS Growth
- GKOS N/A
- MSW 18.78
- EPS
- GKOS N/A
- MSW 0.20
- Revenue
- GKOS $383,481,000.00
- MSW $31,769,612.00
- Revenue This Year
- GKOS $27.84
- MSW N/A
- Revenue Next Year
- GKOS $27.99
- MSW N/A
- P/E Ratio
- GKOS N/A
- MSW $16.88
- Revenue Growth
- GKOS 21.85
- MSW 30.91
- 52 Week Low
- GKOS $77.91
- MSW $2.12
- 52 Week High
- GKOS $163.71
- MSW $10.58
- Technical
- Relative Strength Index (RSI)
- GKOS 41.57
- MSW N/A
- Support Level
- GKOS $86.16
- MSW N/A
- Resistance Level
- GKOS $94.55
- MSW N/A
- Average True Range (ATR)
- GKOS 6.54
- MSW 0.00
- MACD
- GKOS 1.11
- MSW 0.00
- Stochastic Oscillator
- GKOS 54.51
- MSW 0.00
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.